{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"Suicide gene activation and elimination of transduced cells will be established through administration of ganciclovir in case of cytokine-release syndrome (CRS) and other MLM-CAR44.1 T-cell related toxicities.","groups":[{"description":"Patients were scheduled to receive a single intravenous (iv) infusion of CD44v6.CAR-transduced autologous lymphocytes at day 0, after lymphodepleting chemotherapy with cyclophosphamide iv (500 mg/m2) and fludarabine iv (30 mg/m2) performed daily from day -5 to day -3\n\nThe dose of iv infused MLM-CAR44.1 T-cells is:\n\nPHASE I: 0.5x10E6/Kg or 1x10E6/Kg or 2x10E6/Kg according to the BOIN design.","id":"OG000","title":"MLM-CAR44.1 T-cells Infusion"}],"populationDescription":"Data were not collected because no MLM-CAR44.1 T-cell related toxicities occurred","reportingStatus":"POSTED","timeFrame":"At day 7, 14, 21, 28, 60, 90, 180 from infusion, assessed as day 0","title":"Phase I: The Percentage of Patients for Whom Activation of Suicide Gene Was Needed","type":"SECONDARY"}